An Open, Multicenter, Phase I / II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics / Pharmacodynamics and Antitumor Activity of GNC-035 Tetra-specific Antibody Injection in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Latest Information Update: 24 Jul 2024
At a glance
- Drugs GNC 035 (Primary)
- Indications Haematological malignancies; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 22 Nov 2023 Status changed from not yet recruiting to recruiting.
- 06 Oct 2023 New trial record